AstraZeneca Acquires EsoBiotec

EsoBiotec is a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity. By engineering immune cells directly within the patient’s body, the company is eliminating the barriers of traditional cell therapies and unlocking new possibilities for oncology and immune-mediated diseases. Its proprietary ENaBL platform redefines adoptive cell therapy, enabling single IV, off-the-shelf treatments that reduce costs, improve patient experience, eliminate the need for immune cell depletion and have the potential to improve efficacy and safety through advanced lentiviral vector technology. EsoBiotec is based in Mont-Saint-Guibert, Belgium.